528 related articles for article (PubMed ID: 30951600)
1. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
2. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
[TBL] [Abstract][Full Text] [Related]
3. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
Viani RM; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Steimers D; Min S; Wiznia A;
Pediatr Infect Dis J; 2015 Nov; 34(11):1207-13. PubMed ID: 26244832
[TBL] [Abstract][Full Text] [Related]
4. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD; Acosta EP; Liu JP; Gray KP; George K; Montañez N; Popson S; Buchanan AM; Bartlett M; Dayton D; Anthony P; Brothers C; Vavro C; Singh R; Koech L; Vhembo T; Mmbaga BT; Pinto JA; Dobbels EFM; Archary M; Chokephaibulkit K; Ounchanum P; Deville JG; Hazra R; Townley E; Wiznia A;
Lancet HIV; 2022 May; 9(5):e332-e340. PubMed ID: 35489377
[TBL] [Abstract][Full Text] [Related]
6. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
Capetti AF; Sterrantino G; Cossu MV; Orofino G; Barbarini G; De Socio GV; Di Giambenedetto S; Di Biagio A; Celesia BM; Argenteri B; Rizzardini G
PLoS One; 2016; 11(10):e0164753. PubMed ID: 27741309
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
De Miguel R; Rial-Crestelo D; Dominguez-Dominguez L; Montejano R; Esteban-Cantos A; Aranguren-Rivas P; Stella-Ascariz N; Bisbal O; Bermejo-Plaza L; Garcia-Alvarez M; Alejos B; Hernando A; Santacreu-Guerrero M; Cadiñanos J; Mayoral M; Castro JM; Moreno V; Martin-Carbonero L; Delgado R; Rubio R; Pulido F; Arribas JR;
EBioMedicine; 2020 May; 55():102779. PubMed ID: 32408111
[TBL] [Abstract][Full Text] [Related]
8. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
9. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.
Taiwo BO; Zheng L; Stefanescu A; Nyaku A; Bezins B; Wallis CL; Godfrey C; Sax PE; Acosta E; Haas D; Smith KY; Sha B; Van Dam C; Gulick RM
Clin Infect Dis; 2018 May; 66(11):1689-1697. PubMed ID: 29253097
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.
Castagna A; Ferrara M; Galli L; Comi L; Sterrantino G; Cenderello G; Zaccarelli M; Focà E; Roncadori A; Lazzarin A;
J Antimicrob Chemother; 2018 Jan; 73(1):177-182. PubMed ID: 29077927
[TBL] [Abstract][Full Text] [Related]
12. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
[TBL] [Abstract][Full Text] [Related]
14. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
17. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
[TBL] [Abstract][Full Text] [Related]
19. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
